Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4751998 | 0.97 | CYP2C19 (0.34) | CYP2C19 | |
| Hydrochloric Acid SCHEMBL4750038 | 0.97 | CYP2C19 (0.34) | CYP2C19 | |
| SCHEMBL2570514 | 0.97 | — | — | |
| SCHEMBL14720462 | 0.92 | — | — | |
| SCHEMBL14129008 | 0.86 | — | — | |
| SCHEMBL3370793 | 0.86 | — | — | |
| SCHEMBL17850692 | 0.79 | — | — | |
| SCHEMBL15368823 | 0.78 | PIM1 (0.34) | — | |
| SCHEMBL9051801 | 0.78 | CYP2C19 (0.38) | CYP2C19USP2TSHR | |
| SCHEMBL17399998 | 0.77 | MCHR1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668162-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | Novartis AG (CH) | 2013-12-04 | — | — | EP | claimed |
| EP-2608669-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2012101062-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | claimed |
| WO-2012027236-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | claimed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222363-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-9597310-B2 | Indanyloxydihydrobenzofuranylacetic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-20160235706-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-18 | — | — | US | disclosed |
| US-9255223-B2 | Polymerizable compounds and liquid crystal media | MERCK PATENT GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| EP-2970146-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014140246-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| EP-2668162-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| EP-2124965-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008090210-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | WO | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CYP2C19 19/4885USP2 3845/4885TSHR 3226/4885 |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | CYP2C19 2904/4885USP2 400/4885TSHR 4787/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CYP2C19 19/4885USP2 3845/4885TSHR 3226/4885 |
| US-20160235706-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPBAR1, GPR52 | CYP2C19 941/4885USP2 3456/4885TSHR 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.